Pyrosequencing for detection of lamivudine-resistant hepatitis B virus

Journal of Clinical Microbiology

Volumn 42, Issue 10, 2004, Pages 4788-4795

  Lindström, Anna ^a,c   Odeberg, Jacob ^b   Albert, Jan ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ARTICLE; CONTROLLED STUDY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

BASE SEQUENCE; DIPHOSPHATES; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 5444249657     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.10.4788-4795.2004     Document Type: Article

References (11)

1. + T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J. Virol. 65:2019-2023.
2. Das, K., X. Xiong, H. Yang, C.E. Westland, C. S. Gibbs, S. G. Saraftanos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:4771-4779.
3. Lok, A. S. F., F. Zoulim, S. Locarnini, A. Mangia, G. Niro, H. Decraemer, G. Maertens, F. Hulstaert, K. de Vreese, and E. Sablon. 2002. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40:3729-3734.
4. O'Meara, D., K. Wilbe, T. Leitner, B. Hejdeman, J. Albert, and J. Lundeberg. 2001. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J. Clin. Microbiol. 39:464-473.
5. Ronaghi, M., M. Uhlén, and P. Nyrén. 1998. A sequencing method based on real-time pyrophosphate. Science 281:363-365.
6. Sarafianos, S. G., K. Das, A. D. Clark, Jr., J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 96:10027-10032.
7. Schuurman, R., D. Brambilla, T. de Groot, D. Huang, S. Land, J. Bremer, I. Benderes, and C. A. B. Boucher. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18:243-248.
8. Severini, A., X. Y. Liu, J. S. Wilson, and D. L. J. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2́,3́-dideoxy-3́-thiacytidine. Antimicrob. Agents Chemother 39:1430-1435.
9. Stuyver, L. J., S. A. Locarnini, A. S. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
10. Tiollais, P., and M. Buendia. 1991. Hepatitis B virus. Sci. Am. 246:116-123.
11. Wong, D. K., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effects of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann. Intern. Med 119:312-323.